EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Ten‐year clinical outcomes from a randomized trial comparing new‐generation everolimus‐eluting stent versus first‐generation Sirolimus‐eluting stent: Results from the RESET extended study

Hiroki Shiomi iD, Ken Kozuma iD, Takeshi Morimoto, Kazushige Kadota, Kengo Tanabe, Yoshihiro Morino, Toshihiro Tamura, Mitsuru Abe iD, Satoru Suwa, Yoshiaki Ito, Masakazu Kobayashi, Kazuoki Dai iD and 14 more

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30791 ↗

At a glance

Randomisierte kontrollierte Studie in Catheterization and Cardiovascular Interventions, 2023. Written by Hiroki Shiomi and 25 co-authors. Institution: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Major MEDLINE topics: Drug-Eluting Stents, Everolimus, Percutaneous Coronary Intervention, Cardiovascular Agents. Cited 4 times so far (Crossref); 22 references. Funded by: Abbott Vascular.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

New‐generation drug‐eluting stents (DES) achieved technological innovations and reported clinical advantages as compared with first‐generation DES in clinical trials with 3–5 years follow‐up. However, detailed clinical outcome data in very long‐term follow‐up is still scarce.

Objectives

To evaluate 10‐year clinical outcomes after first‐ and new‐generation DES implantation.

Methods

In this extende follow‐up study of the RESET, which is a largest randomized trial comparing everolimus‐eluting stent (EES) with Sirolimus‐eluting stent (SES), the study population consisted of 2892 patients from 84 centers. The primary efficacy and safety endpoints were target lesion revascularization (TLR) and a composite of death or myocardial infarction (MI), respectively. Complete 10‐year follow‐up was achieved in 87.9% of patients.

Results

Cumulative 10‐year incidences of TLR and non‐TLR were not significantly different between EES and SES (13.9% vs. 15.7%, Log‐rank p = 0.20, and 33.4% vs. 31.3%, Log‐rank p = 0.30). The cumulative 10‐year incidence of death/MI was also not significantly different between the groups (32.5% vs. 34.4%, Log‐rank p = 0.18). Cumulative 10‐year incidence of definite stent thrombosis was numerically lower in EES than in SES (1.0% vs. 1.7%, Log‐rank p = 0.16). The lower risk of EES relative to SES was significant for a composite endpoint of target lesion failure (TLF: 19.6% vs. 24.9%, Log‐rank p = 0.001) and target vessel failure (TVF: 26.7% vs. 31.4%, Log‐rank p = 0.006).

Conclusion

During 10‐year of follow‐up, the risks for primary efficacy and safety endpoints were not significantly different between new‐generation EES and first‐generation SES, although EES compared with SES was associated with a lower risk for composite endpoints such as TLF and TVF.

Subjects

MeSH terms (MEDLINE)

Drug-Eluting StentsEverolimusPercutaneous Coronary InterventionCardiovascular AgentsCoronary Artery DiseaseSirolimusHumansMaleFemaleTreatment OutcomeProsthesis DesignAgedMiddle AgedTime FactorsMyocardial InfarctionRisk Factors

Author keywords

coronary interventiondrug-eluting stentslong-term outcome

Substances

EverolimusCardiovascular AgentsSirolimus

Authors and institutions

  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Division of Cardiology, Teikyo University Hospital, Tokyo, Japan.
  • Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
  • Division of Cardiology, Iwate Medical University Hospital, Morioka, Japan.

ORCID profiles: Hiroki Shiomi, Ken Kozuma, Mitsuru Abe, Kazuoki Dai

Funding

  • Abbott Vascular

Cite

APA

Shiomi, H., Kozuma, K., Morimoto, T., Kadota, K., Tanabe, K., Morino, Y., Tamura, T., Abe, M., Suwa, S., Ito, Y., Kobayashi, M., Dai, K., Nakao, K., Tarutani, Y., Taniguchi, R., Nishikawa, H., Yamamoto, Y., Yamasaki, T., Okamura, A., …, & RESET Investigators (2023). Ten‐year clinical outcomes from a randomized trial comparing new‐generation everolimus‐eluting stent versus first‐generation Sirolimus‐eluting stent: Results from the RESET extended study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30791

Vancouver

Shiomi H, Kozuma K, Morimoto T, Kadota K, Tanabe K, Morino Y, et al. Ten‐year clinical outcomes from a randomized trial comparing new‐generation everolimus‐eluting stent versus first‐generation Sirolimus‐eluting stent: Results from the RESET extended study. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30791

BibTeX
@article{Shiomi2023,
  author = {Shiomi, Hiroki and Kozuma, Ken and Morimoto, Takeshi and Kadota, Kazushige and Tanabe, Kengo and Morino, Yoshihiro and Tamura, Toshihiro and Abe, Mitsuru and Suwa, Satoru and Ito, Yoshiaki and Kobayashi, Masakazu and Dai, Kazuoki and Nakao, Koichi and Tarutani, Yasuhiro and Taniguchi, Ryoji and Nishikawa, Hideo and Yamamoto, Yoshito and Yamasaki, Tomohiro and Okamura, Atsunori and Nakagawa, Yoshihisa and Ando, Kenji and Kobayashi, Koichi and Kawai, Kazuya and Hibi, Kiyoshi and Kimura, Takeshi and RESET Investigators, RESET Investigators},
  title = {Ten‐year clinical outcomes from a randomized trial comparing new‐generation everolimus‐eluting stent versus first‐generation Sirolimus‐eluting stent: Results from the RESET extended study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30791}
}
Start for free →